<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30061228</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>08</Month>            <Day>06</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>06</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1791-7530</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>38</Volume>                    <Issue>8</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>Anticancer research</Title>                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.</ArticleTitle>            <Pagination>                <MedlinePgn>4617-4627</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.12766</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Protein kinase CK2 was recently identified as a promising therapeutic target for combination therapy. Our study aims to investigate the anticancer effect of a simultaneous inhibition of thymidylate synthase (TS) and CK2 in MCF-7 breast cancer and CCRF-CEM leukemia cells.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The type of interaction between CK2 inhibitors: CX-4945, 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi), or recently obtained 4,5,6,7-tetrabromo-2-methyl-1H-benzimidazol-1-yl)acetonitrile (2b) and TS-directed anticancer drug, 5-fluorouracil (5-FU) was determined using the MTT assay and a combination index method. The influence of the combined treatment on apoptosis in leukemia cells, as well as on cell-cycle progression and the levels of TS, CK2α and P-Ser529-p65 were determined in both cell lines, using flow cytometry and western blot analysis, respectively.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The best synergistic effect was observed in CCRF-CEM cell line with the combination of 5-FU and 2b which correlated with a decrease in the endocellular CK2 activity and enhancement of the pro-apoptotic effect.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The obtained results demonstrate the ability of CK2 inhibitors to enhance the efficacy of 5-FU in anticancer treatment, indicating a different molecular mechanism of the studied CK2 inhibitors interaction with 5-FU.</AbstractText>                <CopyrightInformation>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wińska</LastName>                    <ForeName>Patrycja</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland pwinska@ch.pw.edu.pl.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Skierka</LastName>                    <ForeName>Katarzyna</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Łukowska-Chojnacka</LastName>                    <ForeName>Edyta</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koronkiewicz</LastName>                    <ForeName>Mirosława</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, Warsaw, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cieśla</LastName>                    <ForeName>Joanna</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bretner</LastName>                    <ForeName>Maria</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Chair of Drug and Cosmetics Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Anticancer Res</MedlineTA>            <NlmUniqueID>8102988</NlmUniqueID>            <ISSNLinking>0250-7005</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C555142">5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic acid</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009287">Naphthyridines</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>E24GX49LD8</RegistryNumber>                <NameOfSubstance UI="C031000">benzimidazole</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.1.1.45</RegistryNumber>                <NameOfSubstance UI="D013940">Thymidylate Synthase</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.1</RegistryNumber>                <NameOfSubstance UI="D047390">Casein Kinase II</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.1</RegistryNumber>                <NameOfSubstance UI="C570325">casein kinase 2, alpha, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>U3P01618RT</RegistryNumber>                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047390" MajorTopicYN="N">Casein Kinase II</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009287" MajorTopicYN="N">Naphthyridines</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013940" MajorTopicYN="N">Thymidylate Synthase</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">4,5,6,7-tetrabromo-1H-benzimidazole</Keyword>            <Keyword MajorTopicYN="N">5-fluorouracil</Keyword>            <Keyword MajorTopicYN="N">CX-4945</Keyword>            <Keyword MajorTopicYN="N">Synergism</Keyword>            <Keyword MajorTopicYN="N">protein kinase CK2</Keyword>            <Keyword MajorTopicYN="N">thymidylate synthase</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>06</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30061228</ArticleId>            <ArticleId IdType="pii">38/8/4617</ArticleId>            <ArticleId IdType="doi">10.21873/anticanres.12766</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>